Literature DB >> 15309908

Stimulation of the subthalamic nucleus compared with the globus pallidus internus in patients with Parkinson disease.

Antonella Peppe1, Mariangela Pierantozzi, Andrea Bassi, Maria Grazia Altibrandi, Livia Brusa, Alessandro Stefani, Paolo Stanzione, Paolo Mazzone.   

Abstract

OBJECT: The authors compared the effects of deep brain stimulation (DBS) in the globus pallidus internus (GPi) with those in the subthalamic nucleus (STN) in patients with Parkinson disease (PD) in whom electrodes had been bilaterally implanted in both targets.
METHODS: Eight of 14 patients with advanced PD in whom electrodes had been implanted bilaterally in both the GPi and STN for DBS were selected on the basis of optimal DBS effects and were studied 2 months postsurgery in off- and on-stimulus conditions and after at least 1 month of pharmacological withdrawal. Subcutaneous administration of an apomorphine test dose (0.04 mg/kg) was also performed in both conditions. Compared with the off status, the results showed less reduction in the Unified PD Rating Scale Section III scores during DBS in the GPi (43.1%) than during DBS of the STN (54.5%) or DBS of both the STN and GPi (57.1%). The difference between the effects of DBS in the GPi compared with that in the STN or simultaneous DBS was statistically significant (p < 0.01). In contrast, no statistical difference was found between DBS in the STN and simultaneous DBS in the STN and GPi (p < 0.9). The improvement induced by adding apomorphine administration to DBS was similar in all three stimulus modalities. The abnormal involuntary movements (AIMs) induced by apomorphine were almost abolished by DBS of the GPi, but were not affected by stimulation of the STN. The simultaneous stimulation of STN and GPi produced both antiparkinsonian and anti-AIM effects.
CONCLUSIONS: The improvement of parkinsonian symptoms during stimulation of the GPi, STN, and both nuclei simultaneously may indicate a similar DBS mechanism for both nuclei in inducing antiparkinsonian effects, although STN is more effective. The antidyskinetic effects produced only by DBS of the GPi, with or without STN, may indicate different mechanisms for the antidyskinetic and antiparkinsonian activity related to DBS of the GPi or an additional mechanism in the GPi. These findings indicate that implantation of double electrodes for DBS should not be proposed as a routine procedure, but could be considered as a possible subsequent choice if electrode implantation for DBS of the STN does not control AIMs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15309908     DOI: 10.3171/jns.2004.101.2.0195

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  18 in total

1.  Allosteric modulation of the group III mGlu4 receptor provides functional neuroprotection in the 6-hydroxydopamine rat model of Parkinson's disease.

Authors:  Matthew J Betts; Michael J O'Neill; Susan Duty
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

2.  Failure of long-term subthalamic nucleus stimulation corrected by additional pallidal stimulation in a patient with Parkinson's disease.

Authors:  Niels Allert; Alfons Schnitzler; Volker Sturm; Mohammad Maarouf
Journal:  J Neurol       Date:  2011-12-06       Impact factor: 4.849

3.  Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson's disease.

Authors:  P J Austin; M J Betts; M Broadstock; M J O'Neill; S N Mitchell; S Duty
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

4.  Network modulation in the treatment of Parkinson's disease.

Authors:  Kotaro Asanuma; Chengke Tang; Yilong Ma; Vijay Dhawan; Paul Mattis; Christine Edwards; Michael G Kaplitt; Andrew Feigin; David Eidelberg
Journal:  Brain       Date:  2006-07-14       Impact factor: 13.501

5.  Spontaneous sleep modulates the firing pattern of parkinsonian subthalamic nucleus.

Authors:  Alessandro Stefani; Salvatore Galati; Antonella Peppe; Andrea Bassi; Mariangela Pierantozzi; Atticus H Hainsworth; Giorgio Bernardi; Antonio Orlacchio; Paolo Stanzione; Paolo Mazzone
Journal:  Exp Brain Res       Date:  2005-11-18       Impact factor: 1.972

Review 6.  Deep brain stimulation for Parkinson's disease.

Authors:  Patricia Limousin; Irene Martinez-Torres
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

Review 7.  The deep brain stimulation of the pedunculopontine tegmental nucleus: towards a new stereotactic neurosurgery.

Authors:  Paolo Mazzone; Stefano Sposato; Angelo Insola; Eugenio Scarnati
Journal:  J Neural Transm (Vienna)       Date:  2011-02-12       Impact factor: 3.575

8.  Antiparkinsonian potential of targeting group III metabotropic glutamate receptor subtypes in the rodent substantia nigra pars reticulata.

Authors:  M Broadstock; P J Austin; M J Betts; S Duty
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

Review 9.  The treatment of movement disorders by deep brain stimulation.

Authors:  Hong Yu; Joseph S Neimat
Journal:  Neurotherapeutics       Date:  2008-01       Impact factor: 7.620

10.  Deep brain stimulation of the internal pallidum in Huntington's disease patients: clinical outcome and neuronal firing patterns.

Authors:  Cécile Delorme; Alister Rogers; Brian Lau; Hélène Francisque; Marie-Laure Welter; Sara Fernandez Vidal; Jérôme Yelnik; Alexandra Durr; David Grabli; Carine Karachi
Journal:  J Neurol       Date:  2015-11-14       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.